Ledipasvir/Sofosbuvir for 8 Weeks in Non-Cirrhotic, Treatment Naive Patients with Genotype 1 Hepatitis C Infection: Real Life Experience in a Community Setting

Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India

“…Real world experiences have shown high SVR 12 rates (91-98%) in patients treated with SOF/LDV with or without RBV in patients with genotype 1, including patients with cirrhosis and those who were treatment experienced. [9][10][11][12][13][14][15][16][17][18] However, most of these studies are from the developed countries like United States, United Kingdom, Italy, Spain and Germany. [9][10][11][12][13][14][15][16][17][18] There are no real world studies from the Asian subcontinent and developing countries like India.…”

Hepatitis C: efficacy and safety in real life

“…Analyses from Spanish, Polish and USA studies showed serious adverse events in no more than 6% of patients and discontinuations due to adverse events in 0.8%-2.3%. 17,19,20 Discontinuation due to adverse events were also rare (<1%) in transplant recipients treated with LDV/SOF, but severe adverse events in this difficult population were reported in 9.4% and 11% of American and European populations respectively. 21,22…”

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

“…Last, the English National Health Service guidance recommends 8 weeks of LDV/SOF for noncirrhotic treatment‐naïve genotype 1 HCV infected patients regardless of HCV viral load . Several heterogeneous real‐world cohort studies have reported excellent SVR rates for patients treated for 8 weeks with LDV/SOF±ribavirin …”